{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:17:06Z","timestamp":1784297826221,"version":"3.55.0"},"reference-count":37,"publisher":"Society for Neuroscience","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":199,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"name":"Hungarian Brain Research Program","award":["2017-1.2.1-NKP-2017-00002"],"award-info":[{"award-number":["2017-1.2.1-NKP-2017-00002"]}]},{"DOI":"10.13039\/501100011019","name":"NKFIH","doi-asserted-by":"crossref","award":["EFOP-3.6.1-16-2016-00004"],"award-info":[{"award-number":["EFOP-3.6.1-16-2016-00004"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"NKFIH","doi-asserted-by":"crossref","award":["EFOP-3.6.2-16-2017-00008"],"award-info":[{"award-number":["EFOP-3.6.2-16-2017-00008"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"NKFIH","doi-asserted-by":"crossref","award":["SNN125143"],"award-info":[{"award-number":["SNN125143"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"name":"New National Excellence Program","award":["\u00daNKP-17- 4 -I.- PTE-311"],"award-info":[{"award-number":["\u00daNKP-17- 4 -I.- PTE-311"]}]},{"name":"Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary","award":["20765\/3\/2018\/FEKUSTRAT"],"award-info":[{"award-number":["20765\/3\/2018\/FEKUSTRAT"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["eNeuro"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson\u2019s disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in Hungary from 2010 to 2016 by conducting a nationwide, retrospective study of health administrative data of human subjects. Interrupted time series analyses were performed to explore changes in user trends after the EMA recommendations. We found that TMZ use in PD decreased by 6.56% in each six-month interval after the EMA intervention [a change in trend of \u2212530.22, 95% confidence interval (CI) = \u2212645.00 to \u2212415.44,<jats:italic>p<\/jats:italic>&lt; 0.001 and a decrease in level of \u2212567.26, 95% CI = \u2212910.99 to \u2212223.53,<jats:italic>p<\/jats:italic>\u2009=\u20090.005 12\u2009months postintervention]. TMZ discontinuation was the highest immediately after the intervention, however, its rate slowed down subsequently (a change in trend of \u221249.69, 95% CI = \u221285.14 to \u221214.24,<jats:italic>p<\/jats:italic>\u2009=\u20090.11 without significant level effects). The rate of new TMZ prescriptions did not reduce significantly, therefore, the decreased overall use was mainly attributable to the increased rate of discontinuation only. The main indications for TMZ use were circulatory system disorders, especially angina pectoris, however, off-label utilization was also considerable (40%). The EMA recommendations on TMZ use seem to be only moderately effective in Hungary. Although the number of patients with PD on the drug modestly decreased after the EMA restrictions, TMZ is still widely used in PD for both on-label and off-label indications.<\/jats:p>","DOI":"10.1523\/eneuro.0452-20.2021","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T17:53:40Z","timestamp":1618595620000},"page":"ENEURO.0452-20.2021","source":"Crossref","is-referenced-by-count":2,"title":["Trimetazidine Use in Parkinson\u2019s Disease: Is It a Resolved Problem?"],"prefix":"10.1523","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0734-6878","authenticated-orcid":false,"given":"D\u00e1vid","family":"Pint\u00e9r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Bereczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Ajtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Oberfrank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Janszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.32"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-019-0633-7"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.4","unstructured":"Cochrane Effective Practice and Organisation of Care (2017) Interrupted time series (ITS) analyses. EPOC Resources for Review Authors. Accessed December 16, 2019. Available from https:\/\/epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/public\/uploads\/Resources-for-authors2017\/analysis_in_epoc_reviews.pdf."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.5","unstructured":"Commission nationale de pharmacovigilance (2009) Compte rendu de la r\u00e9union du mardi 19 mai 2009. Accessed December 21, 2019. Available from: http:\/\/dev4-afssaps-marche2017.integra.fr\/var\/ansm_site\/storage\/original\/application\/61c6847bb097168d0bfe266d5515ec7b.pdf."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.6","doi-asserted-by":"publisher","DOI":"10.1159\/000332369"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.7","unstructured":"European Medicines Agency (2012a) European Medicines Agency recommends restricting use of trimetazidine-containing medicines. Available at https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-restricting-use-trimetazidine-containing-medicines."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.8","unstructured":"European Medicines Agency (2012b) Assessment Report for trimetazidine containing medicinal products. Available at https:\/\/www.ema.europa.eu\/en\/documents\/referral\/trimetazidine-article-31-referral-assessment-report_en.pdf."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.9","unstructured":"European Medicines Agency (2014) Assessment report procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. Available at https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-article-31-referral-prac-assessment-report_en.pdf."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.10","doi-asserted-by":"publisher","DOI":"10.1556\/OH.2012.29423"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.08.008"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.10.006"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26960"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.12.002"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.15","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12228"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317368"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.18","doi-asserted-by":"publisher","DOI":"10.1159\/000497613"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.05.016"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.08.018"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.21","first-page":"392","article-title":"[Trimetazidine-induced parkinsonism.]","volume":"19","year":"2004","journal-title":"Neurologia"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.22","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005061"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.23","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005090"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.01.005"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66692-5"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.07.001"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.28","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462303000576"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.29","unstructured":"R\u00e9union de la Commission d\u2019AMM du 7 avril 2011 (2011) Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Accessed December 21, 2019. Available from https:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/25177bda9799352a37801c45677b83d0.pdf."},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2007.12.001"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20574"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3389\/fneur.2019.00640","article-title":"Linking individual patient data to estimate incidence and prevalence of Parkinson\u2019s disease by comparing reports of neurological services and pharmacy prescription refills at a nationwide level","volume":"10","year":"2019","journal-title":"Front Neurol"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.33","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvx029"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2013.11.049"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.35","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13610"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.36","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4675"},{"key":"2023041302154727000_8.3.ENEURO.0452-20.2021.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001304"}],"container-title":["eneuro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/ENEURO.0452-20.2021","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/ENEURO.0452-20.2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T10:05:51Z","timestamp":1681380351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eneuro.org\/lookup\/doi\/10.1523\/ENEURO.0452-20.2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1523\/ENEURO.0452-20.2021"],"URL":"https:\/\/doi.org\/10.1523\/eneuro.0452-20.2021","relation":{},"ISSN":["2373-2822"],"issn-type":[{"value":"2373-2822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]}}}